

REMARKS

Claims 21-39 are pending in the present application.

Restriction Requirement

The Examiner has required election in the present application between:

Group I, claims 22-25, drawn to compounds and compositions of formula 1, when D is tetrazolylphenyl and A is optionally substituted phenyl, as well as claims 21, 26 and 33-34 in part;

Group II, claims 27, 31-32, drawn to compounds and composition of formula 1, when D is optionally substituted phenyl (excluding tetrazolyl) and A is optionally substituted phenyl, as well as claims 21, 26 and 33-34 in part; and

Group III, claim 29, drawn to compounds and composition, wherein D is carboxyl substituted benzyl, A is phenyl, as well as claims 21, 26 and 33-34 in part; and

Group IV, claim 30, drawn to compounds and compositions, wherein R^1 and D forms –
 $CHR^2-CH_2-CHR^f-CH_2-$, as well as claims 21, 26 and 33-34 in part; and

Group V, claims 21, 26, 33-34, drawn to the remaining compounds and compositions not encompassed by Groups I-IV; and

Group VI, claims 35-39, drawn to method of treating disorders through blocking chloride channel..

For the purpose of examination of the present application, Applicants elect, without traverse, Group I, Claims 22-25 (and claims 21, 26 and 33-34 reading on the elected compounds).

Upon a finding of allowability over the prior art of the elected claims, Applicants respectfully request rejoinder of the claims of Group VI, which are directed to methods of using the compounds of the elected claims.

Election of species

The Examiner further requires, with the election of Group I, an election of a single disclosed species. **For the purpose of examination of the present application, Applicants elect as a single Species, the compound of Example 18 on page 43, lines 25-26 in the PCT publication, i.e., the compound N-(4-Chloro-3-trifluoromethyl-phenyl)-N'-[4-(acrylic acid methyl ester)-2-(1H-tetrazol-5-yl)-phenyl]urea.**


Claims 21-26 and 34 are generic to the elected species. The Examiner is requested expand the search and examination of the claimed invention to additional species, upon a finding of novelty and unobviousness of the elected species.

Should there be any outstanding matters that need to be resolved in the present application, the Examiner is respectfully requested to contact MaryAnne Armstrong, Ph.D., Registration No 40,069 at the telephone number of the undersigned below, to conduct an interview in an effort to expedite prosecution in connection with the present application.

If necessary, the Commissioner is hereby authorized in this, concurrent, and future replies, to charge payment or credit any overpayment to our Deposit Account No. 02-2448 for any additional fees required under 37 C.F.R. § 1.16 or under § 1.17; particularly, extension of time fees.

Dated: JUL 23 2008

Respectfully submitted,

By 
MaryAnne Armstrong, Ph.D.
Registration No.: 40,069
BIRCH, STEWART, KOLASCH & BIRCH, LLP
8110 Gatehouse Road
Suite 100 East
P.O. Box 747
Falls Church, Virginia 22040-0747
(703) 205-8000
Attorney for Applicant